The Journal of Immunology, Vol 144, Issue 5 1549-1553, Copyright © 1990 by American Association of Immunologists

ARTICLES

The Ba fragment of complement factor B inhibits human B lymphocyte proliferation

JL Ambrus Jr, MG Peters, AS Fauci and EJ Brown
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.

Normal human B lymphocyte function is finely regulated by both positive and negative signals at each stage of activation, proliferation, and differentiation. Activation signals include antigen and surface Ig cross-linking agents such as anti-mu or anti-delta. Signals inducing proliferation include IL-2, high m.w.-B cell growth factor (BCGF), and low m.w.-BCGF. IL-2 as well as IL-6 and other partially characterized B cell differentiation factors can induce terminal differentiation of proliferating B cells into Ig-secreting plasma cells. Various C components have been described to regulate B cell function including Bb that enhances proliferation, C5a that enhances Ig production, and C3a that inhibits Ig production. In our study, we examined the ability of the factor B cleavage fragment Ba to influence human B cell function. Ba did not affect the activation of resting B cells but inhibited the proliferation of activated B cells stimulated with either high m.w.- BCGF or low m.w.-BCGF. The inhibition occurred with doses of Ba as low as 1 microgram/ml (29 nM). Ba was found to bind to activated human B lymphocytes in a saturable manner with an apparent K of approximately 25 nM and an apparent Bmax of 56,000 sites/cell. A peptide made of the carboxy terminal 10 amino acids of Ba (GHGPGEQQKR), was also found to inhibit growth factor induced proliferation of activated B cells but at an ID50 of approximately 5 microM. Finally, Ba was found to inhibit the terminal differentiation of Staphylococcus aweus Cowan-activated B cells stimulated with B cell differentiation factors but not Ig secretion by the partially differentiated EBV-transformed cell line SKW.6. Thus, concentrations of Ba achievable in vivo at sites of active inflammation were found to act on human B lymphocytes by inhibiting their proliferation. This may act to limit the immune response to a specific antigenic challenge.

This article has been cited by other articles:

				Y. Huang, P. M. Krein, D. A. Muruve, and B. W. Winston Complement Factor B Gene Regulation: Synergistic Effects of TNF-{alpha} and IFN-{gamma} in Macrophages J. Immunol., September 1, 2002; 169(5): 2627 - 2635. [Abstract] [Full Text] [PDF]

				P. R. Taylor, J. T. Nash, E. Theodoridis, A. E. Bygrave, M. J. Walport, and M. Botto A Targeted Disruption of the Murine Complement Factor B Gene Resulting in Loss of Expression of Three Genes in Close Proximity, Factor B, C2, and D17H6S45 J. Biol. Chem., January 16, 1998; 273(3): 1699 - 1704. [Abstract] [Full Text] [PDF]

				M. Matsumoto, W. Fukuda, A. Circolo, J. Goellner, J. Strauss-Schoenberger, X. Wang, S. Fujita, T. Hidvegi, D. D. Chaplin, and H. R. Colten Abrogation of the alternative complement pathway by targeted deletion of murine factor B PNAS, August 5, 1997; 94(16): 8720 - 8725. [Abstract] [Full Text] [PDF]